Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3013998 | Revista Española de Cardiología | 2010 | 21 Pages |
Abstract
In recent years, several studies have shown that right ventricular function is an important predictor of survival in patients with congenital heart disease, pulmonary hypertension or left heart failure. Our understanding of right heart failure has improved considerably over the last two decades. In this review article, our objective was to provide a critical summary of the evidence underlying the management of right heart failure. A systematic review of the literature was performed using PubMed and the latest issue of the Cochrane Central Register of Controlled Trials to identify studies conducted between January 1975 and January 2010. The literature search encompassed observational studies, randomized controlled trials and meta-analyses. The evidence underlying the use of beta-blockade, angiotensin-converting enzyme inhibitors, inhaled nitric oxide, hydralazine, warfarin, and resynchronization therapy in right heart failure was systematically reviewed. Emerging new therapies, such as metabolic modulators, and the pearls and pitfalls of managing right heart failure are also discussed in the article.
Keywords
BREHPTECDAVDFEVITGVFEVDPAPmRVPiNONYHAPDE5EACTDFPCPÓxido nítrico inhaladoICIRevisión sistemáticaventrículo derechoventrículo izquierdoTetralogia de FallotGasto cardiacoICDInsuficiencia cardiaca agudaHipertensión arterial pulmonarHipertensión pulmonar tromboembólica crónicaRight heartSystematic reviewAcute heart failureInsuficiencia cardiacaheart failurePADHipertensión pulmonarPulmonary hypertensionfracción de eyección del ventrículo izquierdoHAp
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Mehdi Skhiri, Sharon A. Hunt, André Y. Denault, François Haddad,